<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01121926</url>
  </required_header>
  <id_info>
    <org_study_id>04ACL108</org_study_id>
    <nct_id>NCT01121926</nct_id>
  </id_info>
  <brief_title>A Study to Compare the Bioavailability of 300 mg Trazodone Hydrochloride Extended-release Caplets and 100 mg Trazodone Hydrochloride Immediate-release Tablets at Steady State</brief_title>
  <official_title>A Randomized, Two-way Crossover Study to Compare the Bioavailability of 300 mg Trazodone Hydrochloride Extended-release Caplets (Containing Contramid®) (Administered Once Daily) and 100 mg Trazodone Hydrochloride Immediate-release Tablets (Administered Three Times Daily) at Steady State</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Labopharm Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Labopharm Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study was to compare the pharmacokinetic profiles at steady state of the
      test product, 300 mg trazodone hydrochloride (HCl) extended-release caplets (containing
      Contramid®), when administered once daily, and the reference product, 100 mg trazodone HCl
      immediate-release tablets (Apotex Corp.), when administered three times daily, for one week.
      For this purpose, the rate and extent of absorption of trazodone and formation of
      m-chlorophenylpiperazine (mCPP) after administration of multiple doses of up to 300 mg of
      each of the two formulations was compared.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence Based on Cmax,ss</measure>
    <time_frame>9 days</time_frame>
    <description>Cmax,ss = Maximum plasma concentration (Cmax) at steady state (ss): (Cmax,ss). Measured in nanograms per milliliter (ng/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioequivalence Based on AUCss</measure>
    <time_frame>9 days</time_frame>
    <description>AUCss = Area under the plasma concentration curve (AUC) vs. time data pairs at steady state (ss): AUCss.
Measured in nanograms x hours per milliliter (ng*h/mL).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Minimum Plasma Concentration (Cmin,ss)</measure>
    <time_frame>9 days</time_frame>
    <description>Minimum plasma concentration at steady state (Cmin,ss). Measured in nanograms per milliliter (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration at 24 Hours Post-evening Dose (C24h)</measure>
    <time_frame>9 days</time_frame>
    <description>Plasma concentration at 24 hours post-evening dose (C24h) in nanograms per milliliter (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Peak Exposure (Tmax)</measure>
    <time_frame>9 days</time_frame>
    <description>Time to peak exposure (Tmax) at steady state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Swing</measure>
    <time_frame>9 days</time_frame>
    <description>Percentage swing is a pharmacokinetic parameter calculated as follows:
((Cmax,ss - Cmin,ss)/Cmin,ss)*100.
Where:
Cmax,ss = Maximum concentration at steady state; Cmin,ss = Minimum concentration at steady state.
It was calculated over 24 hours on day 9.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Peak-Trough Fluctuation (%PTF)</measure>
    <time_frame>9 days</time_frame>
    <description>Percentage Peak-Trough Fluctuation (%PTF) of trazodone calculated as [100*(Cmax-Cmin)/Cav].
Cmax: Maximum plasma concentration Cmin: Minimum plasma concentration Cav: Average plasma concentration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy Subjects</condition>
  <condition>Bioavailability</condition>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Trazodone HCl OAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OAD: Once A Day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trazodone HCl (Apotex Corp.)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trazodone HCl</intervention_name>
    <description>Dosage form:
Extended-release caplets containing 300 mg trazodone HCl and extended-release caplets containing 150 mg trazodone HCl (the 150 mg dosage form was only used for the up and down titration, and was not evaluated in the study).
Dose regimen:
75 mg trazodone HCl (½ x 150 mg extended-release caplet) on Days 1 and 11, 150 mg trazodone HCl (one extended-release caplet) on Days 2 and 10, 300 mg trazodone HCl (one extended-release caplet) on Days 3 to 9, each at 23:30 after a fast of at least 4 hours.</description>
    <arm_group_label>Trazodone HCl OAD</arm_group_label>
    <other_name>Oleptro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trazodone HCl</intervention_name>
    <description>Dosage form:
Immediate-release tablet containing 100 mg trazodone HCl
Dose regimen:
100 mg trazodone HCl (one immediate-release tablet) once (at 23:30) on Days 1 and 11, 100 mg trazodone HCl (one immediate-release tablet) twice (at 23:30 and 11:30) on Days 2 and 10, 100 mg trazodone HCl (one immediate-release tablet) three times daily (at 23:30, 07:30 and 15:30) on Days 3 to 9. Evening doses were administered after a fast of at least 4 hours.</description>
    <arm_group_label>Trazodone HCl (Apotex Corp.)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female subjects 18 to &lt;56 years of age.

          -  Body mass within 10% of ideal mass in relation to height and age, according to Body
             Mass Index.

          -  Body mass not less than 60 kg.

          -  Findings within the range of clinical acceptability in medical history and physical
             examination, and laboratory results within the reference ranges for the relevant
             laboratory tests (unless the investigator considered the deviation to be irrelevant
             for the purpose of the study).

          -  Normal electrocardiogram (ECG) and vital signs, or abnormalities which the
             investigator did not consider a disqualification for participation in the study.

          -  Willingness to undergo pre- and post-study physical examinations and laboratory
             investigations.

          -  Ability to comprehend and willingness to sign both statements of informed consent (for
             screening and phase-related procedures).

          -  Non-smoker or past smoker who stopped the use of any form of tobacco, including snuff
             or similar products, at least 3 months before entering the study.

          -  For females, the following conditions had to be met:

               1. had been surgically sterilized or undergone a hysterectomy, or

               2. was of childbearing potential, and all of the following conditions were met:

                    1. Had a negative pregnancy test at screening. If this test was positive, the
                       subject was to be excluded from the study before receiving study medication.
                       In the circumstance that a pregnancy was discovered after the subjects
                       received the study medication, every attempt had to be made to follow such
                       subjects to term.

                    2. Had to agree to use an accepted method of contraception (i.e., spermicide
                       and barrier methods or spermicide and non-hormonal intrauterine
                       contraceptive device). The subject had to agree to continue with the same
                       method throughout the study. Hormonal contraceptives were not allowed.

               3. females not of childbearing potential could also have been included if they had
                  no menstrual period for one year and were considered as post-menopausal.

        Exclusion Criteria:

          -  Evidence of psychiatric disorder, antagonistic personality, poor motivation, emotional
             or intellectual problems likely to limit the validity of consent to participate in the
             study or limit the ability to comply with protocol requirements.

          -  History of, or current compulsive alcohol abuse (&gt;10 drinks weekly), or regular
             exposure to other substances of abuse.

          -  Use of any medication, prescribed or over-the-counter, within 2 weeks prior to the
             first administration of study medication except if this would not affect the outcome
             of the study in the opinion of the investigator.

          -  Participation in another study with an experimental drug, where the last
             administration (of previous study medication) was within 8 weeks before the first
             administration of study medication.

          -  Treatment within the previous 3 months with any drug with a well-defined potential for
             adversely affecting a major organ or system with evidence to this effect.

          -  A major illness during the 3 months before commencement of the screening period.

          -  History of hypersensitivity to the study medication or any related medication.

          -  History of bronchial asthma.

          -  History of epilepsy.

          -  History of porphyria.

          -  Relevant history or laboratory or clinical findings indicative of acute or chronic
             disease, likely to influence study outcome.

          -  Donation or loss of blood equal to or exceeding 500 mL during the 8 weeks before the
             first administration of study medication.

          -  Diagnosis of hypotension made during the screening period.

          -  Diagnosis of hypertension made during the screening period or current diagnosis of
             hypertension.

          -  Resting pulse of &gt; 100 beats per minute or &lt; 40 beats per minute during the screening
             period, either supine or standing.

          -  Positive testing for HIV and/or Hepatitis B and/or Hepatitis C.

          -  Positive urine screen for drugs of abuse.

          -  Positive urine screen for tobacco use.

          -  A serum pregnancy test (beta human chorionic gonadotropin [β-HCG]) either positive or
             not performed or lactation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=17925</url>
    <description>Approved labelling</description>
  </link>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2010</study_first_submitted>
  <study_first_submitted_qc>May 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2010</study_first_posted>
  <results_first_submitted>June 22, 2010</results_first_submitted>
  <results_first_submitted_qc>July 21, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 16, 2010</results_first_posted>
  <last_update_submitted>April 25, 2012</last_update_submitted>
  <last_update_submitted_qc>April 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy subjects</keyword>
  <keyword>Bioavailability</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Trazodone</keyword>
  <keyword>Steady-state</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trazodone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Test (Trazodone Contramid® OAD) First</title>
          <description>Trazodone Contramid® OAD (Once-A-Day) test product (300 mg tablet administered once daily) dosed in first treatment phase followed by Trazodone IR (Apotex Corp.) reference product (100 mg tablet administered thrice daily) dosed in the second treatment phase. A drug-free period of 7 calendar days separated the last administration of study medication in Phase 1 and the first administration of study medication in Phase 2.
IR = Immediate Release.</description>
        </group>
        <group group_id="P2">
          <title>Reference (Trazodone IR [Apotex Corp.]) First</title>
          <description>Trazodone IR (Apotex Corp.) reference product (100 mg tablet administered thrice daily) dosed in first treatment phase followed by Trazodone Contramid® OAD (Once-A-Day) test product (300 mg tablet administered once daily) dosed in the second treatment phase. A drug-free period of 7 calendar days separated the last administration of study medication in Phase 1 and the first administration of study medication in Phase 2.
IR = Immediate Release.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Positive pregnancy test</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
          <description>Includes groups randomized to receive Trazodone Contramid® OAD (Once-A-Day) test product first and Trazodone IR (Apotex Corp.) reference product first.
IR = Immediate Release</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.7" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bioequivalence Based on Cmax,ss</title>
        <description>Cmax,ss = Maximum plasma concentration (Cmax) at steady state (ss): (Cmax,ss). Measured in nanograms per milliliter (ng/mL).</description>
        <time_frame>9 days</time_frame>
        <population>The dataset for pharmacokinetic analysis comprised the 27 subjects who completed the study as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Trazodone Contramid® OAD</title>
            <description>Trazodone Contramid® OAD test product (300 mg tablet administered once daily) dosed in either period. A drug-free period of 7 calendar days separated the last administration of study medication in Phase 1 and the first administration of study medication in Phase 2.</description>
          </group>
          <group group_id="O2">
            <title>Trazodone HCl (Apotex Corp.)</title>
            <description>Trazodone HCl (Apotex Corp.) reference product (100 mg tablet administered thrice daily) dosed in either period. A drug-free period of 7 calendar days separated the last administration of study medication in Phase 1 and the first administration of study medication in Phase 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Bioequivalence Based on Cmax,ss</title>
          <description>Cmax,ss = Maximum plasma concentration (Cmax) at steady state (ss): (Cmax,ss). Measured in nanograms per milliliter (ng/mL).</description>
          <population>The dataset for pharmacokinetic analysis comprised the 27 subjects who completed the study as per protocol.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1812.026" spread="620.625"/>
                    <measurement group_id="O2" value="3117.778" spread="757.508"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence is established when the ratio of geometric Least Squares means (LSmeans) and confidence interval calculated from the exponential of the difference between the Test and Reference product for the ln-transformed parameter Cmax,ss is between 80% and 125%.</non_inferiority_desc>
            <param_type>Mean ratio</param_type>
            <param_value>56.53</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>49.99</ci_lower_limit>
            <ci_upper_limit>63.94</ci_upper_limit>
            <estimate_desc>Test/reference (%)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bioequivalence Based on AUCss</title>
        <description>AUCss = Area under the plasma concentration curve (AUC) vs. time data pairs at steady state (ss): AUCss.
Measured in nanograms x hours per milliliter (ng*h/mL).</description>
        <time_frame>9 days</time_frame>
        <population>The dataset for pharmacokinetic analysis comprised the 27 subjects who completed the study as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Trazodone Contramid® OAD</title>
            <description>Trazodone Contramid® OAD test product (300 mg tablet administered once daily) dosed in either period. A drug-free period of 7 calendar days separated the last administration of study medication in Phase 1 and the first administration of study medication in Phase 2.</description>
          </group>
          <group group_id="O2">
            <title>Trazodone HCl (Apotex Corp.)</title>
            <description>Trazodone HCl (Apotex Corp.) reference product (100 mg tablet administered thrice daily) dosed in either period. A drug-free period of 7 calendar days separated the last administration of study medication in Phase 1 and the first administration of study medication in Phase 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Bioequivalence Based on AUCss</title>
          <description>AUCss = Area under the plasma concentration curve (AUC) vs. time data pairs at steady state (ss): AUCss.
Measured in nanograms x hours per milliliter (ng*h/mL).</description>
          <population>The dataset for pharmacokinetic analysis comprised the 27 subjects who completed the study as per protocol.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29131.374" spread="9930.767"/>
                    <measurement group_id="O2" value="33058.024" spread="8006.118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence is established when the ratio of geometric Least Squares means (LSmeans) and confidence interval calculated from the exponential of the difference between the Test and Reference product for the ln-transformed parameter AUCss is between 80% and 125%.</non_inferiority_desc>
            <param_type>Mean ratio</param_type>
            <param_value>85.72</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>81.05</ci_lower_limit>
            <ci_upper_limit>90.67</ci_upper_limit>
            <estimate_desc>Test/reference (%)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minimum Plasma Concentration (Cmin,ss)</title>
        <description>Minimum plasma concentration at steady state (Cmin,ss). Measured in nanograms per milliliter (ng/mL)</description>
        <time_frame>9 days</time_frame>
        <population>The dataset for pharmacokinetic analysis comprised the 27 subjects who completed the study as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Trazodone Contramid® OAD</title>
            <description>Trazodone Contramid® OAD test product (300 mg tablet administered once daily) dosed in either period. A drug-free period of 7 calendar days separated the last administration of study medication in Phase 1 and the first administration of study medication in Phase 2.</description>
          </group>
          <group group_id="O2">
            <title>Trazodone HCl (Apotex Corp.)</title>
            <description>Trazodone HCl (Apotex Corp.) reference product (100 mg tablet administered thrice daily) dosed in either period. A drug-free period of 7 calendar days separated the last administration of study medication in Phase 1 and the first administration of study medication in Phase 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Minimum Plasma Concentration (Cmin,ss)</title>
          <description>Minimum plasma concentration at steady state (Cmin,ss). Measured in nanograms per milliliter (ng/mL)</description>
          <population>The dataset for pharmacokinetic analysis comprised the 27 subjects who completed the study as per protocol.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="673.889" spread="354.647"/>
                    <measurement group_id="O2" value="842.763" spread="273.592"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration at 24 Hours Post-evening Dose (C24h)</title>
        <description>Plasma concentration at 24 hours post-evening dose (C24h) in nanograms per milliliter (ng/mL)</description>
        <time_frame>9 days</time_frame>
        <population>The dataset for pharmacokinetic analysis comprised the 27 subjects who completed the study as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Trazodone Contramid® OAD</title>
            <description>Trazodone Contramid® OAD test product (300 mg tablet administered once daily) dosed in either period. A drug-free period of 7 calendar days separated the last administration of study medication in Phase 1 and the first administration of study medication in Phase 2.</description>
          </group>
          <group group_id="O2">
            <title>Trazodone HCl (Apotex Corp.)</title>
            <description>Trazodone HCl (Apotex Corp.) reference product (100 mg tablet administered thrice daily) dosed in either period. A drug-free period of 7 calendar days separated the last administration of study medication in Phase 1 and the first administration of study medication in Phase 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration at 24 Hours Post-evening Dose (C24h)</title>
          <description>Plasma concentration at 24 hours post-evening dose (C24h) in nanograms per milliliter (ng/mL)</description>
          <population>The dataset for pharmacokinetic analysis comprised the 27 subjects who completed the study as per protocol.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="747.270" spread="329.025"/>
                    <measurement group_id="O2" value="919.111" spread="289.382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Peak Exposure (Tmax)</title>
        <description>Time to peak exposure (Tmax) at steady state.</description>
        <time_frame>9 days</time_frame>
        <population>The dataset for pharmacokinetic analysis comprised the 27 subjects who completed the study as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Trazodone Contramid® OAD</title>
            <description>Trazodone Contramid® OAD test product (300 mg tablet administered once daily) dosed in either period. A drug-free period of 7 calendar days separated the last administration of study medication in Phase 1 and the first administration of study medication in Phase 2.</description>
          </group>
          <group group_id="O2">
            <title>Trazodone HCl (Apotex Corp.)</title>
            <description>Trazodone HCl (Apotex Corp.) reference product (100 mg tablet administered thrice daily) dosed in either period. A drug-free period of 7 calendar days separated the last administration of study medication in Phase 1 and the first administration of study medication in Phase 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Peak Exposure (Tmax)</title>
          <description>Time to peak exposure (Tmax) at steady state.</description>
          <population>The dataset for pharmacokinetic analysis comprised the 27 subjects who completed the study as per protocol.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.00" lower_limit="3.00" upper_limit="16.0"/>
                    <measurement group_id="O2" value="8.33" lower_limit="8.33" upper_limit="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Swing</title>
        <description>Percentage swing is a pharmacokinetic parameter calculated as follows:
((Cmax,ss - Cmin,ss)/Cmin,ss)*100.
Where:
Cmax,ss = Maximum concentration at steady state; Cmin,ss = Minimum concentration at steady state.
It was calculated over 24 hours on day 9.</description>
        <time_frame>9 days</time_frame>
        <population>The dataset for pharmacokinetic analysis comprised the 27 subjects who completed the study as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Trazodone Contramid® OAD</title>
            <description>Trazodone Contramid® OAD test product (300 mg tablet administered once daily) dosed in either period. A drug-free period of 7 calendar days separated the last administration of study medication in Phase 1 and the first administration of study medication in Phase 2.</description>
          </group>
          <group group_id="O2">
            <title>Trazodone HCl (Apotex Corp.)</title>
            <description>Trazodone HCl (Apotex Corp.) reference product (100 mg tablet administered thrice daily) dosed in either period. A drug-free period of 7 calendar days separated the last administration of study medication in Phase 1 and the first administration of study medication in Phase 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Swing</title>
          <description>Percentage swing is a pharmacokinetic parameter calculated as follows:
((Cmax,ss - Cmin,ss)/Cmin,ss)*100.
Where:
Cmax,ss = Maximum concentration at steady state; Cmin,ss = Minimum concentration at steady state.
It was calculated over 24 hours on day 9.</description>
          <population>The dataset for pharmacokinetic analysis comprised the 27 subjects who completed the study as per protocol.</population>
          <units>Percentage swing</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="210.769" spread="127.806"/>
                    <measurement group_id="O2" value="302.805" spread="144.467"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Peak-Trough Fluctuation (%PTF)</title>
        <description>Percentage Peak-Trough Fluctuation (%PTF) of trazodone calculated as [100*(Cmax-Cmin)/Cav].
Cmax: Maximum plasma concentration Cmin: Minimum plasma concentration Cav: Average plasma concentration</description>
        <time_frame>9 days</time_frame>
        <population>The dataset for pharmacokinetic analysis comprised the 27 subjects who completed the study as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Trazodone Contramid® OAD</title>
            <description>Trazodone Contramid® OAD test product (300 mg tablet administered once daily) dosed in either period. A drug-free period of 7 calendar days separated the last administration of study medication in Phase 1 and the first administration of study medication in Phase 2.</description>
          </group>
          <group group_id="O2">
            <title>Trazodone HCl (Apotex Corp.)</title>
            <description>Trazodone HCl (Apotex Corp.) reference product (100 mg tablet administered thrice daily) dosed in either period. A drug-free period of 7 calendar days separated the last administration of study medication in Phase 1 and the first administration of study medication in Phase 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Peak-Trough Fluctuation (%PTF)</title>
          <description>Percentage Peak-Trough Fluctuation (%PTF) of trazodone calculated as [100*(Cmax-Cmin)/Cav].
Cmax: Maximum plasma concentration Cmin: Minimum plasma concentration Cav: Average plasma concentration</description>
          <population>The dataset for pharmacokinetic analysis comprised the 27 subjects who completed the study as per protocol.</population>
          <units>Percentage Peak-Trough Fluctuation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.090" spread="28.357"/>
                    <measurement group_id="O2" value="174.768" spread="69.648"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Trazodone Contramid® OAD</title>
          <description>Trazodone Contramid® OAD test product (300 mg tablet administered once daily) dosed in either period. A drug-free period of 7 calendar days separated the last administration of study medication in Phase 1 and the first administration of study medication in Phase 2.</description>
        </group>
        <group group_id="E2">
          <title>Trazodone HCl (Apotex Corp.)</title>
          <description>Trazodone HCl (Apotex Corp.) reference product (100 mg tablet administered thrice daily) dosed in either period. A drug-free period of 7 calendar days separated the last administration of study medication in Phase 1 and the first administration of study medication in Phase 2.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="28"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a publication based on the results of this study is envisaged, approval from the Sponsor will be obtained and a draft manuscript will be submitted to the sponsor for scrutiny and comment. The choice of scientific journal will be mutually agreed on by the principal investigator and the sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Regulatory Affairs</name_or_title>
      <organization>Labopharm Inc.</organization>
      <phone>1 450 686 1017</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

